Description:
Perspectives:
- To set-up another clinical trial with this specific phenotype as the main stratification
factor. Therefore a more aggressive or a more specific systemic treatment (with or
without an immunomodulator) could be proposed to those selected patients in the field of
personalized medicine.
- To evaluate the use of the smear as a surrogate non-invasive technique to biopsy for
immunomonitoring.
- To use the CTC/PD-L1 assay as a liquid biopsy in future clinical trials for
stratification and monitoring of cancer patients undergoing immune checkpoint
treatments. This specific subset of CTCs might represent metastatic cells with a high
potential to escape T cell-mediated lysis and might therefore be the actual targets of
immunotherapy.
Title
- Brief Title: Assessment Study to Evaluate Specific Immune Response in Locally Advanced Cervix Cancer After Radio-chemotherapy
- Official Title: Assessment Study to Evaluate Specific Immune Response in Locally Advanced Cervix Cancer After Radio-chemotherapy (IMMUVIX)
Clinical Trial IDs
- ORG STUDY ID:
ICM-URC 2015/27
- NCT ID:
NCT03255252
Conditions
Interventions
Drug | Synonyms | Arms |
---|
Cisplatin injection | | Cisplatin |
Purpose
Perspectives:
- To set-up another clinical trial with this specific phenotype as the main stratification
factor. Therefore a more aggressive or a more specific systemic treatment (with or
without an immunomodulator) could be proposed to those selected patients in the field of
personalized medicine.
- To evaluate the use of the smear as a surrogate non-invasive technique to biopsy for
immunomonitoring.
- To use the CTC/PD-L1 assay as a liquid biopsy in future clinical trials for
stratification and monitoring of cancer patients undergoing immune checkpoint
treatments. This specific subset of CTCs might represent metastatic cells with a high
potential to escape T cell-mediated lysis and might therefore be the actual targets of
immunotherapy.
Detailed Description
Cervical cancer is a real worldwide health care issue. High-risk human papillomavirus
(HR-HPV) chronic infection is a co-factor in the development of the cervical cancer.
The HR-HPV genome encodes two oncoproteins (E6 and E7) which are required to sustain the
malignant phenotype of pre-neoplastic lesions and are considered as foreign antigens
recognized by the immune system, Many studies have suggested that local immunologic escape
can cause the emergence of HPV-induced cervical cancer Radio-chemotherapy is the gold
standard treatment for locally advanced cervical cancer, resulting in 2 year-control rates of
about 70 to 85 %. A better and earlier understanding of the reasons for tumor escape may
hopefully help to improve these outcomes.
Both radiation and chemotherapy are myelosuppressive treatments, but new treatment modalities
such as Intensity-Modulated Radiation Therapy (IMRT) may allow a more rapid hematologic
recovery. In addition to this immunosuppressive microenvironment, a significant number of
tumor-infiltrating lymphocytes (TILs) are detected in cervical cancer tissue, highlighting
interactions between tumor and immune cells.
Another issue is the fact that cancer cells develop different strategies to bypass the immune
surveillance, such as a down-regulation of class I human leucocyte antigen (HLA) on tumor
cells surface.
Furthermore, there is growing evidence of the importance of immune cells in response to
cervical cancer treatment. TILs have been correlated with cervical cancer patients' outcome.
More precisely, the location and type of these immune cells seem to be of great importance
for the tumor response to treatment.
Receptors with negative regulatory function have been identified on the surface of those T
cells, including CTLA4 and PD1 and seem to play a great role in tumor escape to treatment.
The presence of circulating tumor cells (CTCs) was shown to be correlated with a poor
patient's prognosis in many cancers. A recent study suggested a potential mechanism of immune
escape of these CTCs resulting in metastasis spreading.
The hypothesis of this study is that the frequency of PD1+,CD39+, specific phenotype of the
non-regulatory CD4+ and CD8+ T cells among TILs is involved with the lack of response to the
treatment and correlates with an early relapse after the treatment (i.e. patients with a very
poor prognosis).
Perspectives:
- To set-up another clinical trial with this specific phenotype as the main stratification
factor. Therefore a more aggressive or a more specific systemic treatment (with or
without an immunomodulator) could be proposed to those selected patients in the field of
personalized medicine.
- To evaluate the use of the smear as a surrogate non-invasive technique to biopsy for
immunomonitoring.
- To use the CTC/PD-L1 assay as a liquid biopsy in future clinical trials for
stratification and monitoring of cancer patients undergoing immune checkpoint
treatments. This specific subset of CTCs might represent metastatic cells with a high
potential to escape T cell-mediated lysis and might therefore be the actual targets of
immunotherapy.
Trial Arms
Name | Type | Description | Interventions |
---|
Cisplatin | Experimental | Weekly cisplatin (40 mg/m²) will be administered during radiotherapy. At least 3 cycles of cisplatin should be performed according to the hematological and renal functions but not mandatory. | |
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 18 years.
- HPV-positive cervical cancer proven* by biopsy.
- All FIGO stages cervical cancers which are the matter for radio-chemotherapy and
exclusive brachytherapy indications.
- ECOG performance status ≤2.
- Ability to give informed consent.
- Patients must be affiliated to a Social Security System.
- Patient information and written informed consent form signed.
Exclusion Criteria:
- Adenocarcinoma of cervix.
- Known autoimmune disorder.
- History of HIV and/ or hepatitis infection.
- History of pelvic radiation or radio-chemotherapy.
- Recurrent or metastatic cervical cancer.
- Contra-indication for cisplatin.
- Patient pregnant and/or breastfeeding.
- History of other malignancy within the previous 5 years (except for appropriately
treated melanoma skin carcinoma).
- Patients with psychological, familial, sociological or geographical condition
potentially hampering compliance with the study protocol and follow-up schedule
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | Female |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Expression of CD8+CD39+PD1+ lymphocytes infiltrate on cervix biopsies |
Time Frame: | through study completion, an average of 1 year disease free survival |
Safety Issue: | |
Description: | Cervix biopsies analysis |
Secondary Outcome Measures
Measure: | Effect on 1-year DFS of other putative biomarkers (CD73, CD39, PD1 and Tim3) on the non-regulatory CD4+ and CD8+ lymphocytes |
Time Frame: | through study completion, an average of 1 year disease free survival |
Safety Issue: | |
Description: | Cervix biopsies and blood samples analysis |
Details
Phase: | Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Active, not recruiting |
Lead Sponsor: | Institut du Cancer de Montpellier - Val d'Aurelle |
Last Updated
August 16, 2021